Treponema Palladium Antibody Test

Syphilis is back. After decades of decline, cases have surged across the United States, and the infection often causes no symptoms at all in its early stages. You can carry the bacterium for years without knowing it, while it quietly damages your cardiovascular system, your nervous system, and your organs. A treponemal antibody test is the most reliable way to find out whether you have ever been exposed.

This test looks for antibodies your immune system makes specifically against Treponema pallidum (the spiral-shaped bacterium that causes syphilis). Unlike many blood tests that give you a number on a scale, this one gives you a yes-or-no answer: reactive (positive) or nonreactive (negative). A reactive result means your body has encountered the bacterium at some point. A nonreactive result generally rules out exposure.

How the Antibody Response Works

When Treponema pallidum enters your body, usually through mucous membranes during sexual contact, it multiplies locally and then spreads through your lymphatic system and bloodstream. Your immune system responds by producing two types of antibodies. First come IgM antibodies, which appear early and are short-lived. Then come IgG antibodies, which are more durable and typically persist for life, even after successful treatment.

These antibodies become detectable about 10 to 15 days after the appearance of the initial sore (called a chancre). The bacterium is sometimes called a "stealth pathogen" because its surface proteins are hidden beneath its outer membrane, making it harder for your immune system to detect. Your body does eventually mount an immune response, but that response is usually not strong enough to clear the infection on its own without antibiotic treatment.

What a Positive Result Means

A reactive treponemal antibody test tells you that your body has produced antibodies against the syphilis bacterium. It does not, by itself, tell you whether you have an active infection right now, a past infection that was already treated, or a new reinfection. This is the single most common source of confusion with this test: a positive result does not automatically mean you need treatment today.

To determine whether the infection is active, your result is paired with a second type of test called a nontreponemal test (RPR or VDRL). The combination of the two tells you much more than either alone. If both are positive, active syphilis or recent infection is likely. If the treponemal test is positive but the nontreponemal test is negative, the most common explanation is a previously treated infection, though very early primary syphilis and untreated late latent syphilis are also possibilities.

Syphilis Stages and Why Early Detection Matters

Syphilis progresses through distinct stages, each with different consequences. Primary syphilis produces a painless sore at the site of infection, usually 2 to 6 weeks after exposure. Because the sore is painless and may be in a location you cannot easily see, many people miss it entirely. Secondary syphilis follows 1 to 2 months later, with symptoms that can include a widespread rash, swollen lymph nodes, and fatigue. After that, the infection can enter a latent phase where it produces no symptoms at all but remains detectable through blood tests for antibodies.

Left untreated, syphilis can progress to tertiary disease years or decades later, causing damage to the heart and blood vessels (cardiovascular syphilis), the brain and spinal cord (neurosyphilis), or soft tissues throughout the body. The bacterium spreads to the central nervous system in 25% to 60% of people within 6 weeks of infection, though only about 5% develop neurological symptoms. Eye and ear involvement can occur at any stage.

Cardiovascular Risk

Syphilis does not just affect the organs it directly infects. A large study using the Taiwanese national registry compared over 20,000 syphilis patients with matched controls and found elevated rates of several cardiovascular events.

Sources: Wu et al., European Heart Journal (2024); Chang et al., International Journal of Stroke (2022).

What this means for you: these studies did not fully separate the effects of treated versus untreated syphilis, so it is unclear whether adequate early treatment eliminates the excess cardiovascular risk. But the pattern is consistent: syphilis is not just a localized genital infection. It has systemic consequences, and detecting it early gives you the best chance of preventing them.

Neurological Risk

A combined analysis of multiple studies, pooling data from over 21,000 syphilis patients and 22,000 controls, confirmed significantly higher rates of neurological disease in people with syphilis. Neurosyphilis can cause meningitis (inflammation of the membranes surrounding the brain), progressive cognitive decline, and damage to the spinal cord that affects balance and sensation. Ocular syphilis, which can cause vision loss, and ear-related syphilis, which can cause hearing loss, can occur at any stage of infection.

Congenital Syphilis

If you are pregnant or planning to become pregnant, syphilis screening is especially urgent. Up to 40% of fetuses exposed to syphilis in the womb are stillborn or die shortly after birth. Congenital syphilis cases in the United States increased 106% between 2019 and 2023. Current guidelines recommend screening at the first prenatal visit, again at 28 weeks, and again at delivery.

How This Test Is Interpreted

Treponemal antibody tests are reported as reactive or nonreactive. There is no scale, no "optimal range," and no gray zone in the way you might see with a cholesterol or blood sugar reading. The result tells you whether your immune system has ever produced antibodies against Treponema pallidum.

Because treponemal antibodies typically persist for life regardless of treatment, this test cannot be used to confirm that treatment worked. Treatment monitoring relies on the nontreponemal test (RPR), where a fourfold decline in the numerical titer indicates successful treatment.

Test Sensitivity by Stage

The accuracy of treponemal antibody tests depends on the stage of infection. Automated treponemal immunoassays detect 94.5% to 96.4% of primary syphilis cases, rising to 100% for secondary syphilis. For latent syphilis, sensitivity ranges from 86.8% to 100% depending on the stage and the specific assay used. The older FTA-ABS test performs less well in primary syphilis, catching only about 78% of cases. The TP-PA test has the highest specificity at 100% and is preferred when a second confirmatory treponemal test is needed.

The key gap is at the very beginning: up to 30% of people with early primary syphilis will have a nonreactive result on both treponemal and nontreponemal tests because the immune response has not yet kicked in. If you have a suspicious sore and your initial test is negative, retest in two weeks.

When Results Can Be Misleading

Treponemal antibody tests are highly specific (98% to 100%), meaning false positives are uncommon. But they do occur, and certain groups are more susceptible. A study of 759 false-positive treponemal results found that people under 18, over 45, and males had significantly higher false-positive rates.

Autoimmune diseases are the most common driver of false positives. A retrospective study of nearly 36,000 tests found that patients with false-positive treponemal results had significantly higher rates of autoimmune antibodies (immune proteins that mistakenly attack the body's own tissues). Lupus, a condition in which the immune system attacks healthy tissue throughout the body, is specifically flagged as a cause of false-positive results.

Other infections can also trigger false positives, including HIV, hepatitis C, cytomegalovirus (a common herpes-family virus), and certain tropical infections like yaws, malaria, and tuberculosis. COVID-19 vaccination has been associated with false-positive results as well. Pregnancy, injection drug use, and advanced cancer have also been linked to occasional false positives. Common medications (statins, metformin, corticosteroids, thyroid medications, and others) do not affect treponemal antibody test results. Fasting, exercise, and time of day also do not influence the result.

Treponemal vs. Nontreponemal Tests: Know the Difference

This is the distinction that trips up most people. Treponemal tests (like this one) detect antibodies aimed specifically at proteins on the syphilis bacterium. They are excellent for confirming whether you have ever been exposed but poor for monitoring treatment. Nontreponemal tests (RPR, VDRL) detect a different type of antibody that reacts to fats released when the bacterium damages your cells. These antibodies rise with active disease and fall after successful treatment, making nontreponemal tests the right tool for tracking whether treatment is working.

Most high-volume laboratories now use a "reverse sequence" algorithm, where the automated treponemal test is run first (because it can be automated) and a nontreponemal test is added if the result is reactive. If the two results disagree, a second treponemal test using a different method is performed to break the tie.

Tracking Over Time

For treponemal antibodies, "tracking" means something different than it does for most biomarkers. Because the result is qualitative (reactive or nonreactive) and because antibodies typically persist for life, serial tracking of this specific test is not useful for monitoring disease activity or treatment response. Once you are reactive, you will likely remain reactive permanently. About 15% to 25% of people treated during primary syphilis will revert to nonreactive after 2 to 3 years, but this is the exception.

What you should track instead is the nontreponemal titer (RPR). After treatment, a fourfold decline in RPR titer confirms that the antibiotic worked. If you are at ongoing risk (see the screening recommendations below), repeat screening with the treponemal test is still valuable because a new reactive result in someone who previously reverted to nonreactive, or a rising RPR titer in someone with a stable history, can signal reinfection.

Who Should Get Screened

The USPSTF gives syphilis screening in at-risk populations its highest rating (Grade A), meaning the evidence for benefit is strong. The CDC expanded its recommendations in 2023 to include all sexually active people ages 15 to 44 in high-prevalence counties, which covers about 72% of the U.S. population. For men who have sex with men (MSM), screening at least annually is recommended, with every 3 to 6 months for those at highest risk. People living with HIV should be screened at least annually. Pregnant individuals should be screened at the first prenatal visit, at 28 weeks, and at delivery.

Other groups that benefit from regular screening include people with a history of incarceration, people with multiple or anonymous sexual partners, those who use condoms inconsistently, people who use methamphetamine or inject drugs, and people on HIV pre-exposure prophylaxis (PrEP). More frequent screening (every 3 months vs. annually) detects significantly more cases: one study found 8.1% versus 3.1% early syphilis detection rates in HIV-positive MSM screened quarterly versus annually.